Myriad Genetics, Inc. Stock News

ANGLE PLC (AIM:AGL, OTCQX:ANPCY) has struck a collaboration with Myriad Genetics of the US to explore whether cancer DNA captured from blood can be used alongside existing tumour tissue tests. The liquid biopsy specialist said on Wednesday that blood samples from cancer patients would be processed using its Parsortix system, which isolates whole cancer cells circulating in the bloodstream.

SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been promoted to Chief Financial Officer, effective August 16, 2025.

Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing

Myriad Genetics posted Q2 2025 revenue growth of 1% year-over-year, but adjusted for one-time events, growth would have been 5%. Key growth drivers include expanding Hereditary Cancer Testing to unaffected cancer patients and launching the Precise MRD test for molecular residual disease. Full-year 2025 revenue guidance was raised to $818-$828 million, reflecting confidence in continued growth a...

Myriad Genetics, Inc. (NASDAQ:MYGN ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Mark S. Verratti - Chief Operating Officer Matthew Scalo - Senior Vice President of Investor Relations Samraat S.

Myriad Genetics (MYGN) Q2 Revenue Up 6%

Myriad Genetics announced financial results for its second quarter ended June 30, 2025, updated full-year 2025 financial guidance on business performance.

ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) complied with federal securities laws. On May 6, 2025, Myriad Genetics reported first quarter 2025 financial results, and lowered its 2025 financial guidance, revealing, among other things, a decline in pharmacogenomics revenue by 20%...